Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilead

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

Gilead continues its exec clear-out, licenses antivirals from Novartis

Long-standing R&D chief to depart

- PMLiVE

J&J files new Darzalex formulation in US and Europe

Subcutaneous version could help fend of Sanofi rival

- PMLiVE

Gilead strikes $5.1bn deal to bolster ties with Galapagos

Big boost for Belgian biotech, without a buy-out

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

- PMLiVE

25 Women Leaders in UK Healthcare (part 2)

25 Women in UK healthcare, Part 2   (Click here for Part 1)13. SORAYA BEKKALI Gene therapy pioneerCell and gene therapy is definitely the most exciting development in biopharma research, promising...

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

After discount row, NICE finally says yes to first line Revlimid

England catches up with rest of Europe

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links